alcmi - addario lung cancer medical institute

What alcmi - addario lung cancer medical institute does

Addario Lung Cancer Medical Institute (ALCMI) is a 501c(3) nonprofit international research consortium founded in 2008 by Bonnie J. Addario and Tony Addario, headquartered in San Carlos, California. ALCMI operates a network of 25+ premier oncology research institutions across the United States, France, the United Kingdom, and Italy, focused on accelerating investigator-initiated clinical trials in lung cancer. Its core products are five active or recently active clinical studies (INHERIT, ENIGMA+, EoYLC, SPARK, SUCCEED) addressing young lung cancer, hereditary risk factors, ALK-positive biomarkers, KRAS resistance mechanisms, and small cell lung cancer patient preferences. Operationally, ALCMI provides funding, trial design support, clinical operations staff, biospecimen collection, and a 3,000+ specimen biobank, and runs decentralized/remote observational trials that allow nationwide US patient participation without site visits. All operations adhere to ICH, GCP, and FDA standards.

ALCMI is governed by a board and led by Chairman and CEO Ken Krantz (MD, PhD) and COO Richard Erwin, with a lean staff of approximately seven people across executive, clinical project management, marketing, and finance functions. The organization is funded through three revenue streams: charitable donations and philanthropic support, sponsorships from pharmaceutical and biotech partners (notably Boehringer Ingelheim for SUCCEED and Biodesix for BEACON-LUNG), and government/foundation grants (NIH, DoD). It does not charge patients for trial participation; some trials provide participant stipends (e.g., $350 in SUCCEED). The business model is therefore a hybrid of grant-funded research operations and contract-based industry sponsorship rather than a fee-for-service CRO.

Distribution and awareness rely on a community-led, event-driven go-to-market approach: active participation in ASCO, AACR, World Conference on Lung Cancer, and ESMO; a research blog; and direct engagement with patient advocacy networks, most notably GO2 for Lung Cancer. ALCMI's published research has accumulated 13,659 citations and downloads across 23 completed trials, and its 1,754 enrolled trial participants represent its primary operational output metric. Strategic technology integrations include AI partner Viz.ai for clinical workflow coordination, liquid biopsy partners (Inivata, Resolution Bioscience, Foundation Medicine) for circulating tumor DNA analysis, and Champions Oncology for patient-derived xenograft models in EGFR and ROS1 studies.

Name

alcmi - addario lung cancer medical institute

Legal name

Addario Lung Cancer Medical Institute

Website

https://alcmi.org

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Addario Lung Cancer Medical Institute (ALCMI) is a 501c(3) nonprofit international consortium of 25+ oncology research institutions that designs, funds, and operates investigator-initiated lung cancer clinical trials and maintains a 3,000+ specimen biospecimen bank for academic researchers, pharmaceutical sponsors, and lung cancer patients.

Ownership category

akta.pro rank

Product category

Clinical Trial Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

akta.pro secondary industries

Clinical Trial Site Operations & Study Coordination (HLAGACAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management (HLACAOAI)

Keywords

• Lung cancer research
• Clinical trial services
• Biospecimen banking
• Oncology consortium
• Decentralized clinical trials

Headquarters

HQ city

San Carlos

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Donations and Philanthropic Support: As a 501c(3) nonprofit organization, ALCMI relies on charitable donations from individuals, foundations, and organizations to fund lung cancer research and clinical trials
2. Sponsorship from Industry Partners: Pharmaceutical and biotech companies sponsor specific clinical trials and research initiatives (e.g., Boehringer Ingelheim supports SUCCEED study, Biodesix sponsors BEACON-LUNG)
3. Government and Foundation Grants: NIH, DoD, and foundation grants support research projects and investigator-initiated trials

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

ALCMI accelerates investigator-initiated lung cancer clinical trials by providing funding, trial design support, operational staff, reporting assistance, and biospecimen collection/storage to an international consortium of 25+ premier oncology research institutions. The institute conducts remote, decentralized observational biomarker trials covering five research focus areas: Young Lung Cancer, Inheritable Disease, Resistance Mechanisms, Collaboration, and Specimen Research. It maintains a biospecimen bank with 3,000+ specimens available for study.

Product overview

ALCMI is a nonprofit international consortium of 25+ premier oncology research institutions that accelerates investigator-initiated lung cancer clinical trials. Their portfolio consists of remote, decentralized clinical trial programs focused on five research areas: Young Lung Cancer, Inheritable Disease, Resistance Mechanisms, Collaboration, and Specimen Research. The core offerings include clinical trial design and operational services, access to a 3,000+ specimen biospecimen bank, and specific clinical studies including INHERIT (hereditary lung cancer risk), ENIGMA+ (ALK+ NSCLC biomarkers), EoYLC (young lung cancer epidemiology), SPARK (KRAS resistance), and SUCCEED (small cell lung cancer). All trials adhere to ICH standards, GCP best practices, and FDA regulations.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Research Services End-to-end clinical trial research services providing funding, trial design support, operational staff, reporting assistance, and biospecimen collection/storage for investigator-initiated lung cancer clinical trials.
• INHERIT Study Investigates inherited risk of lung cancer mutations, expanding research to include ALK+, ROS1, KRAS and other genetic mutations across enrolled families.
• ENIGMA+ Study Studies tissue and saliva specimens from patients with ALK-positive lung cancer to elucidate novel immune and genomic markers.
• EoYLC Study Examines environmental and childhood exposures and risk factors for lung cancer in persons under age 50.
• SPARK Study Studies new mutations after treatment in KRAS lung cancer through liquid biopsy analysis to understand drug resistance mechanisms.
• SUCCEED Study Small Cell Lung Cancer Community Engagement to Eliminate Research Discrepancies - remote, decentralized observational study focused on patient preferences and goals in SCLC research.
• Biospecimen Bank Maintains a biospecimen bank with more than 2,000 specimens available for lung cancer research studies.
• Decentralized Clinical Trial Platform Remote, decentralized, observational biomarker trials that enable patients to participate from home without visiting research facilities.

Quantifiable outcome

• 23 completed clinical trials leading to new understanding of oncogene drivers and germline mutations
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

33 partnerships are on record, tiered key, core and supporting.

• Viz.aikeyTechnology or Integration · 4 September 2024Partnership to unite AI and lung cancer research communities. Viz.ai brings AI-powered care coordination across 1,700 hospitals and health systems. Collaboration aims to improve early disease detection, clinical workflows, and patient protocols through applied AI to oncology research.
• GO2 for Lung CancercoreStrategic or Co-development Partner · 17 April 2024Strategic partner in the ORIGINS INITIATIVE and INHERIT study. GO2 provides input on trial design from the patient's experience, elevates awareness among the lung cancer community, and helps navigate people and their families to enrollment. The partnership is part of a multi-year, multi-million-dollar endeavor to uncover inherited lung cancer risk.
• Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 17 April 2024Primary conductor of clinical protocols for INHERIT study, performs all data analysis, and stores biomedical samples at its institutional biorepository. DFCI serves as the lead institution for hereditary lung cancer research collaboration.
• Biodesix, Inc.keyStrategic or Co-development Partner · 31 August 2020Sponsor of BEACON-LUNG study; specializes in liquid biopsy and lung cancer diagnostics. Biodesix provides Primary Immune Response (PIR) test using mass spectrometry with machine learning to classify patients as responders or non-responders.
• Champions OncologysupportingTechnology or IntegrationCompany specializing in Patient Derived Xenograft (PDX) models for EGFR PDX Study and ROS1 PDX Study. Champions Oncology implants and grows patient tumors in immune-deficient mice to create research models.
• InivatasupportingTechnology or IntegrationCompany specializing in liquid biopsy technology for LIBERTI Study. Inivata analyzes blood samples to study changes in circulating tumor cells and DNA in NSCLC patients.
• ScancellsupportingStrategic or Co-development PartnerCollaboration to advance cancer vaccine clinical trials in NSCLC patients. Partnership announced in January 2017 to leverage Scancell's immuno-oncology expertise with ALCMI's research network.
• Resolution BiosciencesupportingTechnology or IntegrationCommercial diagnostic company for SPACEWALK Study liquid biopsy analysis. Specializes in analyzing tumor material found in blood plasma to detect genetic mutations causing drug resistance.
• Foundation MedicinesupportingTechnology or IntegrationCommercial diagnostic company for SPARK Study liquid biopsy analysis. Analyzes blood plasma DNA and sequences to look for genetic changes in KRAS and other genes important to lung cancer.
• Baptist MemorialsupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• Boca Raton Regional HospitalsupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• City of HopesupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• Dignity HealthsupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• El Camino HealthsupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• Gustave RoussysupportingStrategic or Co-development PartnerEuropean consortium partner - Cancer Campus, Villejuif, France
• Harvard Medical SchoolsupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• Massachusetts General HospitalsupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• MemorialCaresupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• MontefioresupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• Northside HospitalsupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• NYU School of MedicinesupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• The Ohio State UniversitysupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network; home to James Thoracic Center
• Palo Alto Medical FoundationsupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• Rush University Medical CentersupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• St. Louis Cancer CaresupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• UC-DavissupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• UC-San DiegosupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• UC-San FranciscosupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• The University of ManchestersupportingStrategic or Co-development PartnerEuropean consortium partner in the ALCMI international research network
• University of TorinosupportingStrategic or Co-development PartnerEuropean consortium partner in the ALCMI international research network
• USC (University of Southern California)supportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network; home to Norris Comprehensive Cancer Center
• Vanderbilt University Medical CentersupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network
• Washington University - St. LouissupportingStrategic or Co-development PartnerConsortium partner in the ALCMI international research network

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Stand Up To Cancer (SU2C): SU2C is a nonprofit that funds collaborative, multi-institution cancer research and investigator-initiated trials through a consortium of leading academic centers. It mirrors ALCMI's nonprofit research consortium model, sponsor-driven funding structure, and cross-institution trial coordination approach, differing primarily in covering multiple cancer types rather than focusing on lung cancer.
• V Foundation for Cancer Research: The V Foundation is a cancer research nonprofit that funds investigator-initiated projects, translational research, and clinical trials across premier cancer centers. Comparable to ALCMI in its philanthropic funding model, focus on accelerating investigator-led science, and ability to convene academic research networks — though it spans all cancer types rather than lung-specific.
• LUNGevity Foundation: LUNGevity is the largest lung-cancer-focused nonprofit in the US, funding research, early detection, and clinical trials while maintaining a patient advocacy and education platform. It is the closest disease-specific analog to ALCMI, with overlapping mission areas (lung cancer survivability, research acceleration, patient navigation) but a heavier emphasis on patient services versus trial operations.
• Lung Cancer Research Foundation (LCRF): LCRF is a lung cancer-specific nonprofit that funds investigator-initiated research grants and clinical studies at academic institutions. Comparable to ALCMI in disease focus, nonprofit grant-making model, and reliance on academic principal investigators, though it operates more as a grant funder than as a trial operator/SMO.
• International Association for the Study of Lung Cancer (IASLC): IASLC is the leading global professional organization dedicated to lung cancer research, education, and clinical guideline development. Comparable to ALCMI in convening the international thoracic oncology research community, sponsoring scientific meetings, and producing peer-reviewed publications, but operating as a professional society rather than a clinical trial operator.
• Translational Research in Oncology (TRIO): TRIO is a global academic clinical research organization that conducts investigator-initiated and sponsored oncology trials across an international network of academic centers. It is highly comparable to ALCMI's operational model — coordinating multicenter oncology trials, providing operational/biostatistical services, and bridging academia with pharma sponsors — though it operates across multiple tumor types.
• Academic Thoracic Oncology Research Consortium (ATORC): ATORC is an academic consortium that runs investigator-initiated thoracic oncology clinical trials across US cancer centers. It mirrors ALCMI's model of multicenter investigator-initiated thoracic trials within a premier-institution network, though ATORC focuses strictly on trial operations whereas ALCMI also runs a biospecimen bank and patient-facing studies.
• National Foundation for Cancer Research (NFCR): NFCR is a nonprofit that funds cancer research and supports investigator-initiated projects, translational platforms, and global collaborations. It is comparable to ALCMI in nonprofit funding model, support for investigator-led science, and international partnerships, though it spans multiple cancer types and emphasizes platform technologies.
• Bonnie J. Addario Lung Cancer Foundation (ALCF): ALCF is ALCMI's sister organization founded by the same co-founders, focused on patient services, education, and community-building for lung cancer patients. It is directly comparable as a lung-cancer-focused nonprofit from the same family of organizations, though ALCF emphasizes patient support while ALCMI emphasizes clinical trial execution.
• Friends of Cancer Research: Friends of Cancer Research is a nonprofit that drives collaboration across cancer research stakeholders on policy, regulatory science, and trial design. Comparable to ALCMI in convening cross-institution research collaboration, but operating primarily as a policy/advocacy organization rather than a trial operator with biospecimen infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ALCMI_research
• Facebookfacebook.com/AddarioLungCancerMedicalInstitute
• LinkedInlinkedin.com/company/addario-lung-cancer-medical-institute-alcmi

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about alcmi - addario lung cancer medical institute